Kết nối với chúng tôi

Liên minh châu Âu cho Cá nhân Y học

EAPM: Phương pháp tiếp cận sự kiện hàng năm của các bên liên quan lần thứ chín, ngày 17 tháng XNUMX trong sự kiện ung thư hàng đầu, hãy đăng ký ngay!

SHARE:

Được phát hành

on

Chúng tôi sử dụng đăng ký của bạn để cung cấp nội dung theo những cách bạn đã đồng ý và để cải thiện sự hiểu biết của chúng tôi về bạn. Bạn có thể bỏ theo dõi bất cứ lúc nào.

Good afternoon, health colleagues, and welcome to the European Alliance for Personalised Medicine (EAPM) update of the week – the time is now ripe to register for the upcoming EAPM event in September that will take place during the ESMO Congress, details below, viết Giám đốc Điều hành EAPM Denis Horgan.

‘All in it together’

The conference, EAPM’s ninth annual event, is entitled ‘Sự cần thiết phải thay đổi - và cách biến điều đó thành hiện thực: Xác định hệ sinh thái chăm sóc sức khỏe để xác định giá trị'. Sự kiện sẽ diễn ra vào Thứ Sáu, ngày 17 tháng 08 từ 30h16–00hXNUMX CET; đây là liên kết để đăng ký và đây là liên kết đến chương trình làm việc.

One of the biggest challenges facing Europe today is cancer in its many forms. More to the point, how do we get the best possible cooperation and coordination among the multi-stakeholders in the field, and unite them under one umbrella to ensure access for current cancer patients, as well as citizens who will be future patients and, very likely, future cancer patients?  And with the leaps in genetic technologies, the emergence of biology-based immunotherapy - which helps the immune system fight cancer - there are many reasons to be hopeful going forward.

All stakeholders will have to play their part in discussions and policy formation during the session. And they will all have to accept that the ultimate objective is better health for patients. Their own interests and priorities must adapt to that priority. 

  • For patients (and physicians) there are more options, durable clinical benefit, reduced exposure to non-effective drugs and potential to leverage current scientific and technological advances; 
  • For the private sector, the potential to tackle core challenges in discovering and developing more effective medicines, to reduce rates of attrition in drug development, and to reduce the associated escalating costs which are central to a more sustainable future and delivery for healthcare needs; 
  • And for healthcare systems and payers, improved efficiency through the provision of efficacious and cost-effective care through the avoidance of ineffective and redundant interventions, are again key to a more sustainable and deliverable future system.
  • For institutions and member states it could mean more purposeful discussion – taking more account of input from stakeholders, avoiding repetition, and translating decisions into action… 

Chuỗi hội nghị bàn tròn về động lực học này sẽ xem xét các yếu tố khác nhau của vấn đề này thông qua các phiên họp sau: 

  • Phần I: Giành được sự tin tưởng của các bên liên quan trong việc chia sẻ dữ liệu bộ gen và sử dụng bằng chứng / dữ liệu thế giới thực
  • Phần II: Đưa chẩn đoán phân tử vào các hệ thống chăm sóc sức khỏe
  • Phần III Điều chỉnh tương lai - Cân bằng giữa an toàn bệnh nhân và tạo điều kiện đổi mới - IVDR
  • Phần IV: Cứu sống thông qua thu thập và sử dụng dữ liệu sức khỏe

From a stakeholder perspective, speakers amongst others will include Niklas Hedberg, UK Professor Sir Mark Caufield, former chief scientist, Genomics England, Monika Brüggemann, department of hematology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany and Paul Hoffman, head of the Laboratory of Clinical and Experimental Pathology at the University Hospital Nice, France.

quảng cáo

Dưới đây là liên kết để đăng ký và đây là liên kết đến chương trình làm việc.

Reform of EU medicines agency: Where do EU institutions stand? 

The Commission's proposal to reinforce the mandate of the European Medicines Agency (EMA) aims to strengthen the Union’s ability to manage and respond to public health emergencies and to ensure the smooth functioning of the internal market for medicinal products and medical devices. The European Parliament recently adopted a proposal to broaden the mandate of the European Medicines Agency ahead of upcoming talks with member states on EMA’s future role. MEPs endorsed their amendments to the proposal to reinforce the EMA mandate, presented by the Commission in November 2020 as part of the efforts to ensure better preparedness for future health emergencies. 

Ủy viên Y tế Stella Kyriakides told the parliament that while EMA is being “absolutely central to our collective efforts to tackle [pandemic]”, a stronger mandate is needed to be “better equipped for the future crisis”. 

Once a compromise agreement is reached in this inter-institutional discussion, known as trilogue, and is confirmed by Parliament’s plenary and the EU Council, the regulation will enter into force. “We need to permanently monitor the shortages of critical medicines, we need to report on the risk of shortages of medical devices during a crisis [and] to catalyse the development and fast approval of medicines with fast track scientific advice and rolling reviews,” Kyriakides nói. 

Some countries indicated they want to hold off on approving the plans until they’ve seen the HERA proposal, due in two weeks, for fear that the agencies’ roles would overlap. But González Casares doesn’t share that concern. “I see no such risk of conflict between the two agencies,” he said. “The pandemic has highlighted the need for governments, institutions and companies to react quickly and effectively to this type of cross-border threats.”

EU’s infectious disease agency: ‘No urgent need’ for coronavirus vaccine booster shots

There’s “no urgent need” for coronavirus vaccine booster shots “based on current evidence,” the EU’s infectious disease agency said on 1 September.

“Evidence based on vaccine effectiveness and duration of protection shows that all vaccines authorised in the EU/EEA are currently highly protective against COVID-19-related hospitalisation, severe disease and death,” the European Centre for Disease Prevention and Control (ECDC) wrote. 

The agency also highlighted that nearly one-third of adults over the age of 18 in the EU and EEA are still not fully vaccinated: “In this situation, the priority now should be to vaccinate all those eligible individuals who have not yet completed their recommended vaccination course.”

The EU announced on Tuesday (31 August) that 70% of adults are fully vaccinated. 

WHO's Hans Kluge warns of ‘difficult autumn’ 

Regional inequalities, a faltering vaccination campaign don’t bode well for the fall months. Warning of the continued threat of the coronavirus, the WHO's Hans Kluge pointed to one projection that shows some 236,000 more deaths in Europe by 1 December. And he pointed out that mortality is rising already — with an 11 percent increase in the number of deaths over the past week — due to the spread of the Delta variant, an easing of public health measures as well as a seasonal increase in travel. 

Kluge also addressed the difficult question of third doses, signalling a shift from the WHO’s previous position, which had asked for a temporary halt on boosters until the end of September to allow the developing world to catch up. “A third dose of vaccine is not a luxury booster taken away from someone who is still waiting for a first jab,” Kluge explained. “It’s basically a way to keep people safe.” But he added that it’s necessary to share doses so everyone could get vaccinated. 

Good news to finish - BioNTech says COVID vaccine is effective against key new strains

The CEO of German pharmaceutical company BioNTech has said he remains confident the company’s Covid vaccine, developed in partnership with Pfizer, will be effective against the highly-infectious variants of the virus discovered in the UK and South Africa. “We are confident that based on the mechanism of our vaccine, even though there are mutations, we believe that the immune response which is induced by our vaccine could also deal with a mutated virus,” Dr. Ugur Sahin, co-founder and CEO of BioNTech, said. 

That is all from EAPM for now, don’t forget to đăng ký for the upcoming EAPM event, and here is the liên kết đến chương trình làm việc.

Chia sẻ bài viết này:

EU Reporter đăng các bài báo từ nhiều nguồn bên ngoài khác nhau thể hiện nhiều quan điểm. Các vị trí được đảm nhận trong các bài báo này không nhất thiết phải là của Phóng viên EU.

Video nổi bật